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Role of Endomucin in Hypoxia-Induced Retinopathy of Prematurity
Abstract
Retinopathy of prematurity (ROP) is a major cause of blindness among premature, low birth weight
infants as a result of pathological angiogenesis. Angiogenesis, the growth of new blood vessels from
preexisting vessels, occurs in the veins and capillaries of the body. The process is highly regulated during
early development and maturation. However, under abnormal conditions such as a decrease in oxygen
levels or hypoxia, angiogenesis can become dysregulated and pathogenic. Currently, the best treatment
for ROP is laser therapy, which does not significantly improve vision. Alternatively, glycoproteins are
believed to play an important role in angiogenesis. Endomucin (EMCN), a glycoprotein, has been shown to
be expressed by the venous and capillary endothelium. EMCN is believed to be associated with
angiogenesis and could be a potential target for treatment of ROP. Thus, we hypothesize that EMCN is
regulated by hypoxia and plays an important role in pathological angiogenesis.
Human retinal endothelial cells (HRECs), representative of endothelial cells involved in retinal
angiogenesis, were deprived of oxygen using a hypoxia chamber. We established the optimal oxygen
dosage, determined the optimal cell density, and monitored EMCN expression at different time points
after exposure to hypoxia. Changes in gene expression in response to hypoxia were compared to control
cells. Our preliminary data indicates that EMCN is regulated by hypoxia. Currently, we are investigating
whether EMCN has similar effects in regulating revascularization in vivo. Taken together, our study
indicates a novel role for EMCN during hypoxia-induced angiogenesis which may serve as a therapeutic
target.
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ABSTRACT
Retinopathy of prematurity (ROP) is a major cause of blindness among premature, low
birth weight infants as a result of pathological angiogenesis. Angiogenesis, the growth of new
blood vessels from preexisting vessels, occurs in the veins and capillaries of the body. The
process is highly regulated during early development and maturation. However, under abnormal
conditions such as a decrease in oxygen levels or hypoxia, angiogenesis can become
dysregulated and pathogenic. Currently, the best treatment for ROP is laser therapy, which does
not significantly improve vision. Alternatively, glycoproteins are believed to play an important
role in angiogenesis. Endomucin (EMCN), a glycoprotein, has been shown to be expressed by
the venous and capillary endothelium. EMCN is believed to be associated with angiogenesis and
could be a potential target for treatment of ROP. Thus, we hypothesize that EMCN is regulated
by hypoxia and plays an important role in pathological angiogenesis.
Human retinal endothelial cells (HRECs), representative of endothelial cells involved in
retinal angiogenesis, were deprived of oxygen using a hypoxia chamber. We established the
optimal oxygen dosage, determined the optimal cell density, and monitored EMCN expression at
different time points after exposure to hypoxia. Changes in gene expression in response to
hypoxia were compared to control cells. Our preliminary data indicates that EMCN is regulated
by hypoxia. Currently, we are investigating whether EMCN has similar effects in regulating
revascularization in vivo. Taken together, our study indicates a novel role for EMCN during
hypoxia-induced angiogenesis which may serve as a therapeutic target.
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